Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | CCT196969 |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | melanoma | sensitive | CCT196969 | Preclinical - Pdx | Actionable | In a preclinical study, CCT196969 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121). | 25500121 |
BRAF V600E | melanoma | sensitive | CCT196969 | Preclinical - Cell culture | Actionable | In a preclinical study, CCT196969 treatment inhibited viability of a melanoma cell line harboring BRAF V600E in culture (PMID: 31618628). | 31618628 |
PubMed Id | Reference Title | Details |
---|---|---|
(25500121) | Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. | Full reference... |
(31618628) | Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. | Full reference... |